Palisade Bio

JD Finley, CEO, and Dr. Mitchell Jones, President & Chief Medical Officer of Palisade Bio, will present at the Needham & Co. 25th Annual Healthcare Conference on Thursday, April 16th from 2:15 PM to 2:55 PM ET in Track 3. For details: bit.ly/4bXeKuP $PALI

Positive topline data from Palisade's Ph. 1b clinical study of PALI-2108 in FSCD support the continued development of PALI-2108 as a potential first therapy designed to address both inflammatory and fibrotic components of Crohn’s disease. Learn more: bit.ly/4sIlbHW $PALI

Mitch Jones, MD, Ph.D., President & Chief Medical Officer of Palisade will present positive topline data from the Phase 1b clinical study of PALI-2108 in FSCD today, April 1st, at the 4th Annual Precision Medicine in IBD Summit. For key clinical findings: bit.ly/4sIlbHW

“These positive data represent an important step in advancing PALI-2108 as a potential first therapy designed to address fibrostenotic complications in Crohn’s disease,” said Mitch Jones, MD, Ph.D., $PALI President & Chief Medical Officer. Read more: bit.ly/4sIlbHW

Tune-in today, March 31st at 8 AM ET for Palisade's webcast discussing the positive topline data from the Phase 1b clinical study evaluating PALI-2108 in patients with #FibrostenoticCrohnsDisease. For webcast details: bit.ly/4s2QZGk $PALI

Palisade today announced positive topline data from its Phase 1b clinical study evaluating PALI-2108 in patients with #FibrostenoticCrohnsDisease. Management will host a conference call and webcast tomorrow, March 31st at 8:00 AM ET, for details: bit.ly/4sIlbHW $PALI

Attending the Leerink Partners 2026 Global Healthcare Conference? Palisade's management team will be available for one-on-one investor meetings. For details: bit.ly/4rg2OZG $PALI #LeerinkGlobalHealthcare

Tune in today, March 2nd at 3:10 PM EST for Palisade's presentation at the TD Cowen 46th Annual Healthcare Conference. Register for the webcast here: bit.ly/4beCHgJ $PALI #TDCowenHealthcare

Palisade's management team will participate in two upcoming investor conferences: - 46th Annual #TDCowenHealthcare Conference on March 2, 2026 at 3:10 PM EST; - #LeerinkGlobalHealthcare on March 8-11, 2026. For details: bit.ly/4rg2OZG $PALI

Tune-in today, February 26th at 12:40 PM ET for a presentation by JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, at the Oppenheimer 36th Annual Healthcare Life Sciences Conference: bit.ly/4qihnv6 $PALI

Phase 1b translational data for PALI-2108 presented at #ECCO26 demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days. View the poster here: bit.ly/3OxjSMX $PALI

“These mechanistic data provide important molecular support for PALI-2108’s colon-targeted design,” said Mitch Jones, M.D., Ph.D., President & Chief Medical Officer of Palisade Bio. Learn about the new translational data for PALI-2108 presented at #ECCO26: bit.ly/4ryMi83

Palisade Bio today announced the presentation of rapid clinical, histologic and new mechanistic colon tissue RNA sequencing data supporting the targeted activity of PALI-2108 at #ECCO26. For key highlights: bit.ly/4ryMi83 $PALI

On Thursday, February 26th at 12:40 PM ET, JD Finley, CEO, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Register for the webcast here: bit.ly/4qihnv6 $PALI

James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio will present a poster (#P0989) at the 21st Congress of #ECCO – Inflammatory Bowel Diseases 2026 on Friday, February 20, 2026, 12:40 – 13:40 CET. For more information: bit.ly/4pDVypD $PALI

Bram Verstockt, MD, PhD is an internationally recognized expert in #inflammatoryboweldisease and a leader in #precisionmedicine and advanced, non-invasive disease assessment. Read more about Palisade's newly appointed CAB member: bit.ly/4cyIoan $PALI #IBD

Palisade Bio today announced the appointment of global IBD precision medicine leader Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Learn more: bit.ly/4cyIoan $PALI

Tune-in today, February 12th at 1:30 PM ET for a virtual fireside chat with JD Finley, CEO, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, at the Piper Sandler Virtual Novel Targets in Immunology Symposium: bit.ly/4anY0e2 $PALI

On Thursday, February 12th, JD Finley, CEO, and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium. Register here: bit.ly/4anY0e2 $PALI

JD Finley, CEO and Dr. Mitchell Jones, President and Chief Medical Officer of Palisade Bio, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12th at 1:30 PM ET bit.ly/4rF9ZuU $PALI